Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Pfizer offers a compelling 6.9% dividend yield, significantly higher than the S&P 500's 1% yield, making it attractive for income investors despite being deeply out of favor on Wall Street. The stock has fallen 60% from its 2021 peak due to disappointing COVID vaccine sales and struggles in drug development, particularly missing out on the lucrative GLP-1 weight-loss drug category. However, the author argues that Pfizer's challenges are typical industry dynamics and the company's strong history suggests it will recover, making it a potential opportunity for long-term investors willing to tolerate near-term uncertainty.